As expected, log-rank test indicated that the presence of anti-ENO1 Ab in patients’ sera was a negative TTFT predictor in univariate analysis: the median TTFT of anti-ENO1 Ab+ CLL patients was 7 months, whereas that of anti-ENO1 Ab- CLL patients was 107 months (p=0.01) (Figure 5B). The gene discussed is ENO1; the disease is B-cell chronic lymphocytic leukemia.